Metabolic peptides — including the GLP-1 incretin class — are studied for appetite regulation and fat loss.
Phase 3 trials in 25,000+ people show ~15% mean body-weight loss vs ~2.4% placebo.
SURMOUNT-1 produced 15-22% weight loss; head-to-head ~20% vs semaglutide's ~14%.
Amylin-receptor agonism suppresses appetite and slows gastric emptying, producing double-digit weight loss in phase 3 trials.
Phase 2 showed up to 24% body-weight loss at 48 weeks at the highest dose.
Phase 3 trials show 15-18% visceral-fat reduction at 26 weeks plus reduced liver fat.
Direct receptor-mediated lipolysis reduces adiposity, well documented in GH-deficient adults.
In mice, prevented diet-induced obesity and improved fat metabolism via AMPK.
GH promotes lipolysis, but no robust human fat-loss trials exist for this combo.
Central melanocortin activation suppresses appetite in animals; human weight data are minimal.
Strong lipolysis in obese rodents, but a 500+ person Phase 2b trial failed its primary weight-loss endpoint.
⚠️ Educational research information only — not medical advice. Many peptides are research-use-only and not approved treatments. Always consult a qualified professional.